Please assess the completion status of the following clinical trial:

Trial Title: Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~Inclusion Criteria:~1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation~2. HIV-1-infected males or females \>= 18 years of age with positive serology confirmed by Western blot~3. No previous antiretroviral treatment (of more than 7 days)~4. Males with CD4+ counts of \< 400 cells/mm3 and females with CD4+ counts of \< 250 cells/mm3~5. NVP- and ATZ/r susceptibility based on HIV-1 genotypic resistance report~6. Adequate renal function defined as a calculated creatinine clearance (CLCr) \>= 50 ml/min according to the Cockcroft-Gault formula~7. Karnofsky score \>= 70~8. Acceptable medical history, as assessed by the investigator~Exclusion criteria:~Exclusion Criteria:~1. Active drug abuse or chronic alcoholism at the investigator's discretion~2. Hepatic cirrhosis stage Child-Pugh B or C~3. Female patients of child-bearing potential who:~   * have a positive serum pregnancy test at screening or during the study,~  * are breast feeding,~  * are planning to become pregnant,~  * are not willing to use a barrier method of contraception, or are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives~4. Laboratory parameters Division of Acquired Immunodeficiency Syndrome (DAIDS) \> grade 2 (triglycerides \> DAIDS grade 3; total cholesterol no restrictions)~5. Active hepatitis B or C disease, defined as HBsAg-positive or Hepatitis C-Virus-Ribo Nucleic Acid (HCV-RNA)- positive with Aspartate Transaminase/Alanine Transaminase (AST/ALT) \> 2.5x Upper Limit of Normal (ULN) (DAIDS grade 1)~6. Hypersensitivity to any ingredients of the test products~7. Have therapy with nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cisplatin, pentamidine, tacrolimus, cyclosporine) or potential competitors of renal excretion (e.g., cidofovir, acyclovir, valacyclovir, ganciclovir, valganciclovir, probenecid, high-dose non-steroidal anti-inflammatory drugs (i.e., ibuprofen)) within 3 months prior to study screening or are expected to receive these during the study~8. Patients who are receiving other concomitant treatments which are not permitted~9. Use of other investigational medications within 30 days before study entry or during the trial~10. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2, chronic treatment with prednisone)~11. Patients with Progressive Multifocal Leukoencephalopathy (PML), Visceral Kaposi's Sarcoma (KS), and/or any lymphoma~12. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit~13. Patients who are receiving systemic treatment for malignant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVP bid (Type: ACTIVE_COMPARATOR): nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
- NVP qd (Type: EXPERIMENTAL): nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
- ATZ/r (Type: ACTIVE_COMPARATOR): ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete